晚期绝症患者有权服用通过一期试验的药物吗？没有。
Should terminally ill patients have the right to take drugs that pass phase I testing? No.
作者信息
Gesme Dean
机构信息
Minnesota Oncology Hematology Professional Association, 800 East 28th Street, Minneapolis, MN 55407-3799, USA.
出版信息
BMJ. 2007 Sep 8;335(7618):479. doi: 10.1136/bmj.39245.429525.AD.
Abstract
The United States is considering allowing experimental drugs to be given to people at the end of life. believes patients should be able to judge the risks for themselves, and counters that use o such drugs outside trials will damage both individuals and science
摘要
美国正在考虑允许在患者生命末期使用实验性药物。（原文此处缺主语）认为患者应该能够自行判断风险，并且反驳称在试验之外使用此类药物会对个人和科学都造成损害。
相似文献
1
Should terminally ill patients have the right to take drugs that pass phase I testing? No.晚期绝症患者有权服用通过一期试验的药物吗？没有。
BMJ. 2007 Sep 8;335(7618):479. doi: 10.1136/bmj.39245.429525.AD.
2
Should terminally ill patients have the right to take drugs that pass phase I testing? Yes.绝症患者有权服用通过一期试验的药物吗？答案是肯定的。
BMJ. 2007 Sep 8;335(7618):478. doi: 10.1136/bmj.39244.451192.AD.
3
Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society.为绝症患者提供试验性癌症药物的非临床试验准入：平衡个人需求和社会需求。
J Med Ethics. 2010 Jun;36(6):367-70. doi: 10.1136/jme.2009.032466. Epub 2010 May 28.
4
[Recent proposals for early stage clinical trials of cancer].[癌症早期临床试验的近期提议]
Gan To Kagaku Ryoho. 1994 Oct;21 Suppl 3:292-4.
5
Clinical trials referral resource. Current clinical trials of fenretinide.临床试验转诊资源。维甲酸的当前临床试验。
Oncology (Williston Park). 2001 Dec;15(12):1595-6, 1598, 1600.
6
[The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].[日本抗癌药物临床评价方法指南的修订]
Gan To Kagaku Ryoho. 2006 Jul;33(7):1015-9.
7
Clinical trials referral resource. Current clinical trials for the proteasome inhibitor PS-341.临床试验转诊资源。蛋白酶体抑制剂PS - 341的当前临床试验。
Oncology (Williston Park). 2000 Nov;14(11):1589-90, 1593-4, 1597.
8
Commentary on "European collaboration in trials of new agents for children with cancer" by Ablett et al.阿布莱特等人对《欧洲儿童癌症新药物试验合作》的评论
Eur J Cancer. 2004 Aug;40(12):1893-5. doi: 10.1016/j.ejca.2004.04.034.
9
Access to experimental drugs in terminally ill patients: a new idea?绝症患者使用实验性药物：一个新想法？
Am J Hosp Palliat Care. 2010 Dec;27(8):509-10. doi: 10.1177/1049909110381462. Epub 2010 Sep 8.
10
Nanoparticle theories slowly turn into practice.
Cancer Discov. 2011 Sep;1(4):280. doi: 10.1158/2159-8290.CD-ND11-06.
引用本文的文献
1
The 'false hope' argument in discussions on expanded access to investigational drugs: a critical assessment.讨论扩大试验性药物的获取途径时的“虚假希望”论点：批判性评估。
Med Health Care Philos. 2022 Dec;25(4):693-701. doi: 10.1007/s11019-022-10106-y. Epub 2022 Aug 11.
2
What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.未满足医疗需求的患者需要什么？荷兰扩大未批准的研究性治疗方法获取途径的患者观点和经验的定性研究。
BMC Med Ethics. 2019 Nov 9;20(1):80. doi: 10.1186/s12910-019-0420-8.
3
Right-to-try laws and individual patient "compassionate use" of experimental oncology medications: A call for improved provider-patient communication.“尝试权”法律与癌症实验药物的患者个体“同情用药”：呼吁改善医患沟通
Death Stud. 2016;40(2):113-20. doi: 10.1080/07481187.2015.1077356. Epub 2015 Aug 27.
本文引用的文献
1
The Society for Clinical Trials opposes US legislation to permit marketing of unproven medical therapies for seriously ill patients.临床试验协会反对美国允许为重症患者推销未经证实的医学疗法的立法。
Clin Trials. 2006;3(2):154-7. doi: 10.1191/1740774506cn141oa.
2
Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study.晚期患者医生预后判断误差的程度及决定因素：前瞻性队列研究
BMJ. 2000 Feb 19;320(7233):469-72. doi: 10.1136/bmj.320.7233.469.
Zotero 插件